UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 2, 2016
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At November 7, 2016, 6,068,355,132 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended October 2, 2016 and September 27, 2015
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended October 2, 2016 and September 27, 2015
Condensed Consolidated Balance Sheets as of October 2, 2016 and December 31, 2015
Condensed Consolidated Statements of Cash Flows for the nine months ended October 2, 2016 and September 27, 2015
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
50
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
51
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
107
Item 4.
Controls and Procedures
107
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
108
Item 1A.
Risk Factors
108
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
109
Item 3.
Defaults Upon Senior Securities
109
Item 4.
Mine Safety Disclosures
109
Item 5.
Other Information
109
Item 6.
Exhibits
110
Signature
111
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2015 Financial Report
Financial Report for the fiscal year ended December 31, 2015, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2015
2015 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2015
AAV
Adeno-Associated Virus
ACA
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Allergan
Allergan plc
Alliance revenues
revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
AM-Pharma
AM-Pharma B.V.
Anacor
Anacor Pharmaceuticals, Inc.
Astellas
Astellas Pharma Inc.
ASU
Accounting Standards Update
ATM-AVI
aztreonam-avibactam
Bamboo
Bamboo Therapeutics, Inc.
Baxter
Baxter International Inc.
BMS
Bristol-Myers Squibb Company
CDC
U.S. Centers for Disease Control and Prevention
Celltrion
Celltrion Inc. and Celltrion Healthcare, Co., Ltd. (collectively)
Developed Markets
U.S., Western Europe, Japan, Canada, Australia, Scandinavia, South Korea, Finland and New Zealand
DEUs
Dividend Equivalent Units
DVT
deep vein thrombosis
EEA
European Economic Area
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GHD
growth hormone deficiency
GIST
gastrointestinal stromal tumors
GIP
Global Innovative Pharmaceutical segment
GPD
Global Product Development organization
GS&Co.
Goldman, Sachs & Co.
HER2-
human epidermal growth factor receptor 2-negative
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical Inc.
IH
Innovative Health
InnoPharma
InnoPharma, Inc.
IPR&D
in-process research and development
IRC
Internal Revenue Code
IRS
U.S. Internal Revenue Service
Janssen
Janssen Biotech Inc.
King
King Pharmaceuticals, Inc.
LDL
low density lipoprotein
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCO
managed care organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
MDV
multi-dose vial
Medivation
Medivation, Inc.
Moody s
Moody s Investors Service
mRCC
metastatic renal cell carcinoma
NDA
new drug application
NOAC
Novel Oral Anticoagulant
NovaQuest
NovaQuest Co-Investment Fund II, L.P. or NovaQuest Co-Investment Fund V, L.P., as applicable
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PBM
Pharmacy Benefit Manager
PCS
Pfizer CenterOne (previously known as Pfizer CentreSource)
PDUFA
Prescription Drug User Fee Act
PE
pulmonary embolism
PGS
Pfizer Global Supply
Pharmacia
Pharmacia Corporation
PP&E
Property, plant & equipment
PTUs
Profit Units
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended October 2, 2016
RAR
Revenue Agent s Report
RCC
renal cell carcinoma
recAP
recombinant human Alkaline Phosphatase
R&D
research and development
RPI
RPI Finance Trust
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
SGA
small for gestational age
S&P
Standard and Poor s
Teuto
Laborat rio Teuto Brasileiro S.A.
TSRUs
Total Shareholder Return Units
U.K.
United Kingdom
U.S.
United States
VAT
value added tax
VOC
Global Vaccines, Oncology and Consumer Healthcare segment
WRD
Worldwide Research and Development
Zoetis
Zoetis Inc.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
October 2,
2016
September 27,
2015
October 2,
2016
September 27,
2015
Revenues
13,045
12,087
39,196
34,804
Costs and expenses:
Cost of sales(a)
3,085
2,219
9,111
6,238
Selling, informational and administrative expenses(a)
3,559
3,270
10,414
9,761
Research and development expenses(a)
1,881
1,722
5,360
5,342
Amortization of intangible assets
968
937
2,934
2,748
Restructuring charges and certain acquisition-related costs
531
581
988
727
Other (income)/deductions net
1,417
661
2,815
670
Income from continuing operations before provision for taxes on income
1,604
2,697
7,575
9,319
Provision for taxes on income
284
567
1,194
2,178
Income from continuing operations
1,320
2,130
6,380
7,141
Discontinued operations net of tax
14
Net income before allocation to noncontrolling interests
1,319
2,139
6,380
7,155
Less: Net income attributable to noncontrolling interests
25
23
Net income attributable to Pfizer Inc.
1,320
2,130
6,355
7,132
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.22
0.34
1.04
1.15
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.22
0.35
1.04
1.15
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.22
0.34
1.03
1.14
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.21
0.34
1.03
1.14
Weighted-average shares basic
6,066
6,168
6,095
6,176
Weighted-average shares diluted
6,138
6,243
6,164
6,259
Cash dividends paid per common share
0.30
0.28
0.90
0.84
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
October 2,
2016
September 27,
2015
October 2,
2016
September 27,
2015
Net income before allocation to noncontrolling interests
1,319
2,139
6,380
7,155
Foreign currency translation adjustments, net
418
(535
999
(2,170
418
(535
999
(2,170
Unrealized holding losses on derivative financial instruments, net
(126
(217
(970
(80
Reclassification adjustments for realized (gains)/losses(a)
150
(35
280
(545
24
(251
(690
(625
Unrealized holding gains/(losses) on available-for-sale securities, net
261
25
740
(502
Reclassification adjustments for realized (gains)/losses(a)
(112
69
(129
815
149
94
611
312
Benefit plans: actuarial losses, net
(82
(144
(101
(122
Reclassification adjustments related to amortization(b)
140
140
418
409
Reclassification adjustments related to settlements, net(b)
28
36
76
98
Other
69
(10
51
120
155
23
444
506
Benefit plans: prior service credits and other, net
95
182
506
Reclassification adjustments related to amortization(b)
(45
(46
(127
(115
Reclassification adjustments related to curtailments, net(b)
(8
(4
(14
(21
Other
(1
12
(3
48
(51
54
366
Other comprehensive income/(loss), before tax
794
(721
1,418
(1,611
Tax provision/(benefit) on other comprehensive income/(loss)(c)
116
(65
111
267
Other comprehensive income/(loss) before allocation to noncontrolling interests
678
(656
1,307
(1,878
Comprehensive income before allocation to noncontrolling interests
1,997
1,483
7,687
5,277
Less: Comprehensive income/(loss) attributable to noncontrolling interests
24
(1
Comprehensive income attributable to Pfizer Inc.
1,997
1,481
7,664
5,278
(a)
Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.
(b)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(c)
See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
October 2,
2016
December 31,
2015
(Unaudited)
Assets
Cash and cash equivalents
2,094
3,641
Short-term investments
12,277
19,649
Trade accounts receivable, less allowance for doubtful accounts: 2016 $672; 2015 $384
9,836
8,176
Inventories
7,507
7,513
Current tax assets
2,825
2,662
Other current assets
2,843
2,154
Assets held for sale
1,119
Total current assets
38,501
43,804
Long-term investments
9,507
15,999
Property, plant and equipment, less accumulated depreciation: 2016 $14,838; 2015 $13,502
13,284
13,766
Identifiable intangible assets, less accumulated amortization
54,238
40,356
Goodwill
56,281
48,242
Noncurrent deferred tax assets and other noncurrent tax assets
1,859
1,794
Other noncurrent assets
4,759
3,420
Total assets
178,430
167,381
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
13,633
10,159
Trade accounts payable
3,476
3,620
Dividends payable
1,821
1,852
Income taxes payable
1,158
418
Accrued compensation and related items
2,048
2,359
Other current liabilities
12,623
10,990
Total current liabilities
34,759
29,399
Long-term debt
30,437
28,740
Pension benefit obligations, net
5,312
6,310
Postretirement benefit obligations, net
1,808
1,809
Noncurrent deferred tax liabilities
31,687
26,877
Other taxes payable
4,767
3,992
Other noncurrent liabilities
6,059
5,257
Total liabilities
114,829
102,384
Commitments and Contingencies
Preferred stock
25
26
Common stock
461
459
Additional paid-in capital
82,534
81,016
Treasury stock
(84,346
(79,252
Retained earnings
72,846
71,993
Accumulated other comprehensive loss
(8,214
(9,522
Total Pfizer Inc. shareholders equity
63,306
64,720
Equity attributable to noncontrolling interests
294
278
Total equity
63,601
64,998
Total liabilities and equity
178,430
167,381
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(MILLIONS OF DOLLARS)
October 2,
2016
September 27,
2015
Operating Activities
Net income before allocation to noncontrolling interests
6,380
7,155
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
4,208
3,733
Asset write-offs and impairments
1,146
864
Write-down of HIS net assets to fair value less estimated costs to sell
1,422
Deferred taxes from continuing operations
(1,335
(165
Share-based compensation expense
532
488
Benefit plan contributions in excess of expense
(775
(804
Other adjustments, net
68
(184
Other changes in assets and liabilities, net of acquisitions and divestitures
(1,718
(1,297
Net cash provided by operating activities
9,929
9,790
Investing Activities
Purchases of property, plant and equipment
(1,134
(786
Purchases of short-term investments
(15,170
(21,068
Proceeds from redemptions/sales of short-term investments
20,685
33,609
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less
6,485
5,557
Purchases of long-term investments
(4,771
(6,578
Proceeds from redemptions/sales of long-term investments
6,915
4,535
Acquisitions of businesses, net of cash acquired
(17,679
(16,322
Acquisitions of intangible assets
(96
(48
Other investing activities, net
60
346
Net cash used in investing activities
(4,704
(756
Financing Activities
Proceeds from short-term borrowings
6,397
2,022
Principal payments on short-term borrowings
(3,321
(16
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less
(963
1,907
Proceeds from issuance of long-term debt
5,031
Principal payments on long-term debt
(4,317
(2,994
Purchases of common stock
(5,000
(6,160
Cash dividends paid
(5,496
(5,211
Proceeds from exercise of stock options
946
1,165
Other financing activities, net
29
171
Net cash used in financing activities
(6,693
(9,115
Effect of exchange-rate changes on cash and cash equivalents
(79
(162
Net decrease in cash and cash equivalents
(1,547
(244
Cash and cash equivalents, beginning
3,641
3,343
Cash and cash equivalents, end
2,094
3,099
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
1,430
1,414
Interest
1,177
1,162
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.
We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.
The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 28, 2016 and August 23, 2015. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 2, 2016 and September 27, 2015.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2015 Form 10-K.
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries.
Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, Pfizer Innovative Health (IH) (previously these businesses were managed as two segments: the GIP segment and the VOC segment). Also, in the second quarter of 2016, we changed the name of our Established Products business to Pfizer Essential Health (EH). We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13.
In the condensed consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets, Other noncurrent assets, Short-term borrowings, including current portion of long-term debt and Long-term debt, and in the condensed consolidated statement of cash flows for the nine months ended September 27, 2015, we performed certain reclassifications to conform to the current presentation of Other changes in assets and liabilities, net of acquisitions and divestitures, Principal payments on short-term borrowings, and Principal payments on long-term debt, for debt issuance costs in accordance with the adoption of a new accounting standard. For additional information, see Note 1B.
On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical will acquire all of Pfizer s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions, and devices. Pfizer has also agreed to certain restrictions on transfer of its ICU Medical shares for at least 18 months. Assets and liabilities associated with HIS were reclassified as held for sale in the condensed consolidated balance sheet as of October 2, 2016. The companies expect to complete the transaction in the first quarter of 2017, subject to customary closing conditions, including required regulatory approvals. For additional information, see Note 2B.
On September 28, 2016 (the acquisition date), we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ($13.9 billion, net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation, and, in accordance with our domestic and international reporting periods, our consolidated financial statements for the three and nine months ended October 2, 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.